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Abstract
Our previous case‐control study observed isolated lymphocytes from 208 individuals 
and determined the differences in the sensitivity to genomic damage of lymphocytes 
derived from cancer patients, pre/suspect cancer patients and healthy volunteers using 
the Comet assay (Anderson et al, 2014). We adapted the LGS technique using a 
slightly different method and examined 700 more blood samples from 598 patients 
with cancer or suspected cancer and 102 healthy individuals. To help increase the 
sensitivity of the test and detect cancer at the level of each individual, we joined with 
the IMSTAR team who analysed our cells with their fully automated Pathfinder™ cell 
reader‐analyser system. With this reading and analysis system 4,000 to 10,000 cells 
were able to be read per slide. The new test which is called TumorScan is a highly 
sensitive test to detect any cancer at an early stage through the response of the white 
blood cells to UV treatment. These patient blood samples have also been collected at 
the stage before confirming diagnosis and treatment. There were four of these indi-
viduals with cancer who had received anti‐cancer treatment. The results from these 
patients showed a reverse pattern compared to non‐treated cancer patients and fol-
lowed the pattern seen in healthy individuals. The results are consistent with the early 
results as reported in the above 2014 paper. Given the results from these samples were 
in a particularly challenging subgroup, whose cancer status was difficult to distin-
guish, the data suggest that the technique using the TumorScan system could exceed 
the area under the ROC curve >93% obtained in the earlier study on a group basis, 
whereas this present study was to detect cancer at an early stage in each individual.
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Greater than 360,000 new cancer cases develop in the UK 
per year, a figure that represents almost 990 cases each day. 
As such, a cancer diagnosis is made every 2 minutes in the 
UK.1 Also, globally, 14.1 million new cases of cancer are di-
agnosed every year.1 More recently using modern genomic 
technology. There was the opportunity to further understand 
the intricacy of interactions between cellular genes and reg-
ulatory genetic elements, which are responsible for pheno-
types resulting in cancer, in addition to further understanding 
the complexity of cancer. However, despite these advance-
ments and occasional successes, most treatments are as yet 
relatively impractical.2
According to sources of the national audit and survey 
data from patients, the tumour site proves the strongest pre-
dictor of multiple consultations. Multiple consultations are 
found in between 30% and 50% of patients subsequently di-
agnosed with multiple myeloma or pancreatic, stomach, or 
lung cancer, compared with <10% multiple consultations of 
patients subsequently diagnosed with breast cancer or mel-
anoma Figure 1.3,4 These distinctions appear to reflect the 
“symptom signature” of various cancers—multiple consulta-
tions are less associated with patients of cancers with specific 
symptoms eg a palpable breast lump or a visible skin lesion), 
are compared to those who were mostly patients present with 
non‐specific symptoms eg back or abdominal pain). As such, 
a marker for the difficulty of detection of a cancer at first pre-
sentation may be considered to be the proportion of patients 
with multiple consultations (Figure 1).5
Therefore, early detection of cancer significantly raises 
the chances for an effective treatment. Cancer identifica-
tion methods are greatly based on imaging, biopsies and 
a few nonspecific biomarkers. The main element of early 
cancer detection is based on education to assist early di-
agnosis and screening. There are new blood tests with a 
high specificity in detecting cancer from healthy individu-
als.6-8 However up to the present time, finding an efficient 
practical method with a low cost and easy approach and 
use in laboratories over the world was not readily available. 
However, Anderson et al. 20149 showed detecting genomic 
damage in lymphocytes from cancer and suspected cancer 
patient samples compared to healthy individuals using the 
Comet assay fulfilled this need. The entirety of the cancers 
tested exhibited responses that were worthy of comparison. 
The test can categorise an individual as positive or negative 
for disease based on a threshold value for a continuous vari-
able (Olive Tail Momenta and % Tail DNAb). Therefore, an 
analysis of Receiver Operating Characteristic curves was 
undertaken based on the 208 individuals. For all cancers, 
as well as pre/suspected‐cancer, the mean log Olive tail 
moments compared to controls resulted in values of area 
under the curve of 0.87 95% CI: 0.82‐0.92). For cancer ver-
sus pre/suspected‐cancer plus controls the value was 0.89 
95% CI: 0.83‐0.95). Finally, for cancer versus controls, ex-
cluding pre/suspected‐cancer, the value was 0.93 95% CI: 
0.88‐0.98) for all 3 values P < 0.001). The test assessed the 
susceptibility of the genome to genetic damage. It is very 
well established that the risk of developing cancer is mostly 
related to inherited or induced genetic mutations. So by im-
plication, this is an assay that evaluates generic, genomic, 
genotoxic processes and is thus an empirical assay of can-
cer susceptibility that does not require an understanding 
of the underlying causative mechanisms.9 In the present 
study, results indicated that characterisation of differences 
in lymphocyte sensitivity to UV again enabled discrimina-
tion between cancer patients, pre/suspect cancer patients 
and healthy volunteers. However, since 2012 to facilitate 
the comet assay method, with UV treatment it was possible 
to standardise the procedure, and we modified the earlier 
LGS technique.10 The new improved system has been ex-
amined on more than 700 individuals eg in Figures 2, 3, 
4 and 5. The order of UV treatment was set from lowest 
and then increasing to the highest UV intensity. The order 
F I G U R E  1  Percentage of patients with cancer who had three or more consultations with a general practitioner before referral. These data 
can be used to categorise cancers as “easier to suspect” (melanoma, breast, endometrial cancer), “harder to suspect” (multiple myeloma, pancreatic, 
ovarian, stomach, lung), or of intermediate diagnostic difficulty. Reprinted from Lyratzopoulos G, Neal RD, Barbiere JM, Rubin GP, Abel GA. 
Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient 
Experience Survey in England. Lancet Oncol 2012;13:353‐65 with permission from Elsevier
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of UV treatment was set as increasing in intensity, starting 
initially with the lowest UV intensity.
The original scoring system was performed using the 
semi‐automated fluorescent Olympus microscope and Komet 
6 software. The number of scored cells was 100 per dose.9,10 
There were some individuals with cancer and suspected can-
cer and healthy controls that did not follow the patterns in the 
damage of DNA in the other samples from the same groups 
Figure 6. These were samples which were difficult to distin-
guish the disease state by comparison with healthy controls.
Sharma et al showed the sensitivity of the in vitro comet 
assay increases with the number of cells scored, for low 
levels of DNA damage, eg scoring of 600 cells increased 
the sensitivity compared with scoring of 100 cells with 
statistical significance. Therefore, in their test it sensitivity 
can be improved by scoring more than 100 cells, using the 
fully‐automated Comet assay scoring.11 The new collab-
oration which includes the modified comet assay plus UV 
treatment (University of Bradford) and the fully‐automated 
Comet assay scoring (PathfinderTM Comet‐imaging sys-
tem from IMSTAR, Paris, France) validated by Jackson et 
al.12 is called TumorScan. We investigated the difficult to 
distinguish samples from two groups of studies, prostate 
and colorectal projects, with both the semi‐automated and 
fully‐automated scoring systems. The sample of pre‐cancer 
and cancer patients in the prostate group: healthy control 
n = 10, BPH n = 5, prostate cancer n = 10 and in the col-
orectal group: healthy control n = 13, polyposis coli n = 10, 
F I G U R E  2  Mean log of the Olive Tail Moment (OTMs) (95% CI) against lymphocyte treated with different doses of UV intensity for all 
groups. In patients with prostate cancer, there was a constant high level of DNA damage after treating with different UV intensity doses. This 
contrasted with patterns for healthy individuals, and benign prostate hyperplasia (BPH) with different levels of response to UV treatment. * presents 
the P‐value <0.01 when the prostate cancer group was compared to the healthy control group
F I G U R E  3  Mean log of the Olive Tail Moment (OTMs) (95% CI) against lymphocytes treated with different doses of UV intensity for 
all groups. In patients with breast cancer, there was a constant high level of DNA damage after treating with different UV intensity doses. This 
contrasted with patterns for healthy individuals, and suspected cancer patients (patients with lumps in breast) with different levels of responses to 
UV treatment. **Presents the P‐value <0.05 when the breast cancer group was compared to the healthy control group.
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colorectal cancer n = 21) selected for reanalysis here repre-
sent a subset of cases where the semi‐automated system could 
not distinguish between patients with cancer and those with 
pre‐cancerous conditions. The sample therefore represents 
the particularly challenging cases (Figures 6, 7 and 8).
For both Olive Tail Moment (OTM) and %Tail DNA 
(TDNA), the mean values in the pre‐cancer group are higher 
than in the cancer group for this selective sub‐sample when 
using the original analysis method.
In the fully‐automated system, data showed the average 
values of both OTM and TDNA are higher in pre‐cancerous 
conditions, compared to controls; they are higher still in can-
cer patients, but the difference between mean values for the 
pre‐cancer and cancer groups is not statistically significant 
in this small sample OTM: P = 0.282; TDNA: P = 0.158). 
There is a statistically significant difference between the can-
cer group and the control group P = 0.007 and P < 0.001, for 
OTM and TDNA, respectively) (Figures 7 and 8).
The data that we presented are the samples that were 
difficult to discriminate between healthy controls and can-
cer patients. The numbers of investigated samples for each 
group are stated in the text. This research was designed as 
F I G U R E  4  Mean log of the Olive Tail Moment (OTMs) (95% CI) against lymphocytes treated with different doses of UV intensity for all 
groups. In patients with lung cancer, there was a constant high level of DNA damage after treating with different UV intensity doses. This contrasted 
with patterns for healthy individuals, and suspected cancer patients (patients with Chronic obstructive pulmonary disease (COPD) with different 
levels of responses to UV treatment. ***Presents the P‐value <0.001 when the lung cancer group was compared to the healthy control group.
F I G U R E  5  Mean log of the Olive Tail Moment (OTMs) (95% CI) against lymphocytes treated with different doses of UV intensity for all 
groups. In patients with colorectal cancer, after treating with different UV intensity doses there was a constant high level of DNA damge. This 
contrasted with patterns for healthy individuals, and suspected cancer patients (patients with polyposis coli) with different levels of responses to UV 
treatment. ***Presents the P‐value <0.001 when the colorectal cancer group was compared to the healthy control group.
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a case‐control study as in the 2014 study and there was a 
10‐15 years gap between the healthy control group and can-
cer groups.  The confounding factors smoking, age, ethnicity, 
drinking habit and gender) for each cancer group lung cancer, 
colorectal cancer, prostate, and breast cancers) were carried 
out using the T‐test as shown in Tables 1, 2, 3, and 4. Results 
shown that, there were no significant differences in any of 
the confounding factors. For breast cancer, only female were 
considered. See the data collection form in Appendix 1.
For the cancer group who have received cancer treatment, 
OTM and TDNA both returned to normal levels, (Figures 7 
and 8).
The results are consistent with the early results reported 
in the Anderson et al paper and, given these results are in 
the very challenging subgroup, the data suggest that the tech-
nique using the fully automated scoring system may even ex-
ceed the area under ROC curve >93% obtained by the early 
LGS system, if in any population there will be blood samples 
of individuals for whom it will be difficult to predict the can-
cer status.
As pointed out by Anderson et al,9 it remains an open 
question whether the increase in damage in cancer cells is a 
predictor of susceptibility or a consequence of disease. We 
know that therapeutics are not involved in this study since 
F I G U R E  6  Prostate group: semi‐automated scoring system 
(difficult to distinguish samples). Group 1 = healthy control, group 
2 = benign prostate hyperplasia, group 3 = prostate cancer and group 
4 = prostate cancer after treatment
F I G U R E  7  Prostate group, automated scoring system (difficult 
to distinguish samples). Group 1 = healthy control, group 2 = BPH, 
group 3 = prostate cancer and group 4 = prostate cancer after 
treatment
F I G U R E  8  Mean log of the %Tail DNA against lymphocytes treated with different doses of UV intensity for all groups. In patients with 
colorectal and prostate cancer, after treating with different UV intensity doses compared to healthy individuals, and suspected cancer patients 
(patients with polyposis coli and BPH) with different levels of responses to UV treatments. Also, the comparison of two various semi‐automated 
and automated (TumorScan) (TS) reading system in colorectal and prostate study groups. (HC = healthy control, SA = semi‐automated, 
A = automated, Scancer = suspected cancer, AT = after treatment). *Represents the P‐value <0.05, when healthy controls group compared to 
cancer group in the automated system and ++ represents the P‐value <0.05 when cancer after treatment group in the automated system compared 
to cancer after treatment group in the semiautomated system.
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patients samples were acquired pre‐diagnosis and thus pre‐
treatment. It was only after obtaining the pathology report 
from the consultant at the clinic that cancer or other disease 
states could be confirmed. It is possible that both suscepti-
bility and cancer status could be involved but this can only 
be ascertained by a long‐ term cohort study over several de-
cades or in a mortality and morbidity study with pooled data 
bases linked to statistics from cancer registries. In terms of 
identifying those at risk of having or developing cancer, this 
uncertainty has no effect on the functionality of the assay be-
cause of its empirical nature and the power of the assay is 
based on this concept. In 2012, Najafzadeh et al suggested 
that by comparing negative control responses with high UVA 
exposure responses, differences in individual cancer risk 
could be considered. However, by incorporating responses 
at different depths in the agar or at different light intensities 
discrimination is enhanced by gaining information about var-
ied UVA intensity‐dependent responses.9
Since that 2014 study, we have conducted two clinical tri-
als, one on colon cancer and the other on prostate cancer and 
samples from a few others eg breast, and the data were exam-
ined in a similar way as in the earlier study bringing our total 
individuals to 908 of whom 196 were controls. In this second 
tranche since 2014, 60 patients were difficult to distinguish 
from controls. It was then that we teamed up with IMSTAR 
for slide scoring. We have worked from the endpoint back-
wards in our own validation, since we have had the cancer 
patient status confirmed by the relevant consultant in the 
clinics. Those samples that belong to other disease states are 
used in research studies with this system. Since this tranche 
is concerned with this new study, where we are predicting at 
an early a stage as possible, the difference between cancer 
patients and controls, we approached IMSTAR to determine 
if their automated system might help since large numbers of 
cells can be scored within minutes with no human interven-
tion, thereby increasing the sensitivity, and as in 2014 there 
is no need for extra enzymes to increase sensitivity.
This final study confirms that the modified method, 
TumorScan ‐ which combines the adapted Comet assay with 
different UV treatments, designed and fully automated cell 
reader‐analyser (IMSTAR PathfinderTM), successfully im-
proves the sensitivity of the original test (LGS test) for the 
detection of samples at the level of the individual.
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ENDNOTES
aOlive Tail Moment is defined as product of distance and normalized in-
tensity integrated over the tail length. A damage measure combining 
T A B L E  1  Confounding factors in lung cancer study
Confounding factors P value
Smoking <0.902
Age <0.354
Ethnicity <0.800
Drinking habit <0.21
Gender <0.178
T A B L E  2  Confounding factors in colorectal cancer study
Confounding factors P value
Smoking <1.08
Age <0.205
Ethnicity <0.902
Drinking habit <1.003
Gender <0.20
T A B L E  3  Confounding factors in prostate cancer study
Confounding factors P value
Smoking <0.95
Age <0.307
Ethnicity <1.401
Drinking habit <0.103
Gender N/A
T A B L E  4  Confounding factors in breast cancer study
Confounding factors P value
Smoking <1.05
Age <0.403
Ethnicity <1.02
Drinking habit <0.108
Gender N/A
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the amount of DNA in the tail with distance of migration (severity of 
damage). 
bPercentage of DNA in Tail is the integrated tail intensity x 100 divided by 
the total integrated cell intensity for a normalized measure of the percent 
of total cell DNA found in the tail. 
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APPENDIX 1
DATA COLLECTION FORM
(To be completed by the Doctor)
STUDY TITLE: Genetic and environmental effects in lymphocytes from different cancerous, precancerous and 
inflammatory conditions using various genetic endpoints
REVIEWED BY LEEDS East RESEARCH ETHICS COMMITTEE (REC)      
(REC REFERENCE NUMBER: 12/YH/0464 )   
PATIENT NUMBER DATE OF SAMPLE
AGE
SEX (PLEASE TICK) M F CONSENT   Y / N
ETHNIC GROUP INFORMATION SHEET Y / N
OCCUPATION
DIET WESTERN ASIAN OMNIVORE VEGETARIAN VEGAN
VITAMINS / ANTI-OXIDANTS
(PLEASE LIST)
PRESCRIBED DRUG USE
(PLEASE LIST)
RECREATIONAL DRUG USE Y/N
IF YES PLEASE LIST
MEDICAL
CANCER
Inflammatory disease                                     
EXTENT SITE HISTOLOGY SURGERY
CANCER
Inflammatory disease
Pre cancerous state
OTHER MEDICAL CONDITIONS
(PLEASE LIST)
Family history of cancer and
Inflammatory disease 
Chemotherapy or radiotherapy
MOST RECENT MEASURE
RESULT DATE RESULT DATE
WEIGHT OTHERS
HEIGHT
BMI
CURRENT SMOKER Y/N PAST SMOKER Y/N HOW MANY/MUCH PER DAY?
CIGARETTES CIGARS PIPE 
ALCOHOL Y/N UNITS PER WEEK
